Risk of cardiovascular disease and all-cause mortality among diabetes patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies
- At: 2011 FIP Congress in Hyderabad (India)
- Type: Poster
- By: YANG, Li (Peking University Third Hospital, Beijing, China)
- Co-author(s): Chen, Xin (Peking University Third Hospital, Beijing, China)
Zhai, Suodi (Peking University Third Hospital, Beijing, China)
Objective: To determine the risk of cardiovascular adverse effects in patients with type 2 diabetes treated with rosiglitazone compared to pioglitazone...
Design: Meta-analysis of retrospective cohort studies using RevMan 5.0 software to calculate risk ratios.
Data sources: The Cochrane Library, PubMed, and Embase were searched to identify relevant The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.